MEDICINOVA INC (MNOV)

US58468P2065 - Common Stock

1.31  -0.01 (-0.76%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNOV. MNOV was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNOV as it has an excellent financial health rating, but there are worries on the profitability. MNOV has a expensive valuation and it also scores bad on growth.



2

1. Profitability

1.1 Basic Checks

In the past year MNOV has reported negative net income.
In the past year MNOV has reported a negative cash flow from operations.
In the past 5 years MNOV always reported negative net income.
In the past 5 years MNOV always reported negative operating cash flow.

1.2 Ratios

MNOV's Return On Assets of -12.93% is amongst the best of the industry. MNOV outperforms 88.18% of its industry peers.
MNOV has a Return On Equity of -13.74%. This is amongst the best in the industry. MNOV outperforms 90.41% of its industry peers.
Industry RankSector Rank
ROA -12.93%
ROE -13.74%
ROIC N/A
ROA(3y)-14.5%
ROA(5y)-15.64%
ROE(3y)-15.3%
ROE(5y)-16.52%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
MNOV has about the same amout of shares outstanding than it did 1 year ago.
MNOV has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

MNOV has an Altman-Z score of 1.59. This is a bad value and indicates that MNOV is not financially healthy and even has some risk of bankruptcy.
MNOV has a better Altman-Z score (1.59) than 70.03% of its industry peers.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.59
ROIC/WACCN/A
WACC9.34%

2.3 Liquidity

A Current Ratio of 15.61 indicates that MNOV has no problem at all paying its short term obligations.
MNOV has a better Current ratio (15.61) than 91.10% of its industry peers.
MNOV has a Quick Ratio of 15.61. This indicates that MNOV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 15.61, MNOV belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.61
Quick Ratio 15.61

0

3. Growth

3.1 Past

MNOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.58%, which is quite impressive.
EPS 1Y (TTM)38.58%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to decrease by -10.79% on average over the next years. This is quite bad
MNOV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y-30.33%
EPS Next 2Y-16.62%
EPS Next 3Y-10.79%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNOV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as MNOV's earnings are expected to decrease with -10.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.62%
EPS Next 3Y-10.79%

0

5. Dividend

5.1 Amount

No dividends for MNOV!.
Industry RankSector Rank
Dividend Yield N/A

MEDICINOVA INC

NASDAQ:MNOV (4/26/2024, 3:30:01 PM)

1.31

-0.01 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap64.26M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.93%
ROE -13.74%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 15.61
Quick Ratio 15.61
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)38.58%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-30.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y